TerminatedPhase 2NCT05053035

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alector Inc.
Principal Investigator
Sabrina Paganoni, MD
Massachusetts General Hospital
Intervention
AL001(drug)
Enrollment
5 enrolled
Eligibility
18 years · All sexes
Timeline
20212022

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05053035 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials